First exercise window for Lumito warrants closes

On 29 November, Lumito AB (publ) (“Lumito”) ended the first exercise period for the Series 2 TO2 subscription warrant. The exercise rate was 72.3 percent, at an exercise price of SEK 1.45 per share.

In total, 11,179,281 new shares have been subscribed during the now concluded first exercise period. Lumito is thus provided approximately MSEK 16.2 in proceeds, before issuance costs. The issuance costs are estimated to be approximately MSEK 0.8. The exercise rate was 72.3 percent. The remaining Series 2 TO2 warrants can be exercised during the period 1 May 2020 to 30 May 2020 inclusive, at an exercise price corresponding to SEK 1.55 per share. Trading in warrants will continue.

As soon as the proceeds from all of the newly subscribed shares (interim shares) have been received by the company, and the issue has been finally registered with the Swedish Companies Registration Office, the interim shares will be automatically converted to regular shares without further notice to the holders. This is projected to take place in week 51.

Through this exercise of warrants, the number of shares outstanding in Lumito increases by 11,179,281, to 70,648,739 shares in total. Simultaneously, the share capital increases by SEK 279,482.02, to SEK 1,766,218.48.

“We are grateful for the great trust that our shareholders are placing in us; the capital we are raising now will bring stability to our forthcoming effort to launch our first product,” says Stefan Nilsson, CEO of Lumito.

G&W Fondkommission has acted as financial adviser to Lumito in connection with the transaction.

For more information, please contact:

Lumito AB (publ), CEO Stefan Nilsson, telefon +46 767 78 59 05, sn@lumito.se
 

This information is information that Lumito AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on December 4, 2019, at 02:00 p.m.

Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers, with UCNP:s as markers, imaging with high quality of for instance tissue samples. The technology has several possible application areas and Lumito has firstly focused on digital pathology. Lumito has an agreement regarding development of instrument and staining kits with TTP plc (The Technology Partnership) in Cambridge UK. Lumito shares LUMITO MTF and warrants are traded at the marketplace NGM Nordic MTF.

Tags:

Subscribe

Documents & Links

Quotes

We are grateful for the great trust that our shareholders are placing in us; the capital we are raising now will bring stability to our forthcoming effort to launch our first product.
Stefan Nilsson, CEO of Lumito